The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients with cardiovascular risk factors and obesity. The study’s primary endpoint ...
If you’ve recently started a journey to lose weight safely yet efficiently, doing cardio for weight loss is key. And there are certain moves that get your heart pumping while helping you reach your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback